A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs ARC 520 (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- Sponsors Arrowhead Pharmaceuticals
- 06 Dec 2017 According to an Arrowhead Pharmaceuticals media release, results from this trial were presented at the 22nd biennial HEP DART meeting.
- 29 Nov 2016 Arrowhead Pharmaceuticals discontinued the development of ARC-520 based upon the discussion with the regulatory agencies regarding the substantial delays in all clinical programs that utilize EX1 and secondly, company has made substantial advances in RNA chemistry and targeting resulting in large potency gains for subQ administered and extra-hepatic RNAi-based development programs. Patients recruitment has been halted and dosing discontinued.
- 29 Nov 2016 Status changed from recruiting to discontinued, as per an Arrowhead Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History